Clyor Inc. – Trademark Portfolio

Entity Type: 03

Clyor Inc. holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include CLYOR, VOICE37, SEASONAL37, VOCAL BOOSTER, and YOUR VOICE YOUR REMEDY. The owner is based in Brooklyn, NY.

# 210

543 Bedford Ave.

Brooklyn, NY 11211

11 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Clyor Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (9 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

3
Cosmetics & Cleaning (6 filings)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does Clyor Inc. have?

Clyor Inc. has 11 U.S. trademarks filed with the USPTO. Of these, 6 registered, 4 abandoned, 1 cancelled.

What trademark classes does Clyor Inc. file in?

Clyor Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Clyor Inc.'s most well-known trademarks?

Clyor Inc.'s registered trademark portfolio includes well-known marks such as CLYOR, VOICE37, SEASONAL37, VOCAL BOOSTER, and YOUR VOICE YOUR REMEDY. These are among 6 currently registered trademarks in the portfolio.

What is Clyor Inc.'s trademark registration success rate?

Clyor Inc. has a 55% trademark registration rate, with 6 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.